Bevacizumab (Avastin) v léčbě refrakterního diabetického makulárního edému
| Title in English | Bevacizumab (Avastin) in treatment of refractory diabetic macular edema |
|---|---|
| Authors | |
| Year of publication | 2009 |
| Type | Article in Proceedings |
| Conference | Sborník abstrakt IX. kongresu ČVRS, Průhonice |
| MU Faculty or unit | |
| Citation | |
| Field | ORL, ophthalmology, stomatology |
| Keywords | diabetic macular edema; bevacizumab |
| Description | Diabetic macular edema (DME) is a serious complication of diabetic retinopathy (DR) and causes a decrease in visual acuity in affected patients. It occurs primarily in type 2 diabetics. Type 1 diabetes is mainly characterized by proliferative changes that cause the traction and vitreous haemorrhage. DME occurs at any stage of DR, ie non-proliferative and proliferative form and is mainly caused by increased vascular permeability of capillary network in the macular area. It leads to the deposition of lipoproteins and thickening of the retina in the central region. In the initial stages of DME is a reversible decrease in visual acuity. Prolonged edema leads to irreversible loss of visual acuity. Bevacizumab (Avastin - Genet, Roche) is an antibody against VEGF-A molecule. It is a complete humanized mouse antibody molecule. This molecule was constructed for the needs of oncology to systemic application. The case studies demonstrated its effect in reducing the thickness of macular edema and improve visual acuity in patients with DME. Intravitreal injection of bevacizumab in 3 consecutive doses in this study group has stabilized visual acuity was thus reversed the negative trend of this disease, which is a gradual decline in visual acuity. Furthermore, there was a decrease in central retina thickness with improvement in the macular anatomy of the macula. This can be explained by stopping a trend of decreasing visual acuity, which causes a gradual decline in visual functions. Intravitreal injection of bevacizumab in accordance with the results achieved in our group is able to stabilize for 4 months visual acuity in patients together with reducing of diffuse macular edema in macula, which leads to an improvement in the anatomy of the macula. |